BioCryst Pharma (BCRX) PT Raised to $13 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.81 +0.77%
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Rating Summary:
16 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 44
Join SI Premium – FREE
JPMorgan analyst Jessica Fye raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $13.00 (from $12.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Crown Castle (CCI) PT Lowered to $91 at BMO Capital Following Mixed Results
- IBM (IBM) PT Raised to $265 at BMO Capital
- FDA approves Orladeyo pellet form for adults and adolescents with HAE
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
